MagForce Nanotechnologies Cuts Jobs, Restructures
Published: Mar 26, 2012
BERLIN, GERMANY--(Marketwire - March 26, 2012) -
MagForce AG / MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
This is a correction of the announcement from 10:24 26.03.2012 CET. Reason for the correction: Correction of year-end 2011 employee number
* Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapy * Start of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical experts * Enhanced activities for international partnerships and initiation of discussions with FDA * Focus on development partnerships and strategic investors to expand patient access and further reduce development costs * Significant decrease in operating expenses expected in 2012 through headcount reduction
Berlin, March 26, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the company's restructuring and revised corporate strategy for 2012. The company reduced its headcount from 41 employees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. The implemented cost reductions will enable the company to work more effectively and concentrate on clinical development activities to support the market introduction of NanoTherm® therapy.
MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, NanoTherm® therapy, for the treatment of brain tumors. Product revenues in 2011 were lower than expected due to the lack of involvement among leading medical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience.
"Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post- market authorization study along with a study in prostate carcinoma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use," said Dr. Andreas Jordan, Management Board and founder of MagForce. "In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market."
"I am delighted to be working closely with leading European key opinion leaders who are pleased to support us in the further development of NanoTherm® therapy and participate in Magforce clinical studies," said Prof. Dr. Hoda Tawfik, VP Clinical Development and Medical Affairs. "Within the multi-center studies, we expect to place two to three new NanoActivator therapy systems in strategic centers before the end of this year."
In 2012, MagForce is pursuing international partnerships, specifically in the US, and plans to initiate discussions with the FDA. Furthermore, the company is in discussion with strategic investors who were not able to participate in recently announced fully-subscribed capital increase, but are interested in future investment opportunities with the company.
ABOUT MAGFORCE AG:
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.
DISCLAIMER: This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward- looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE [HUG#1597261]
Director Investor Relations & Corporate Communications
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email: Email Contact